ResMed expects FY 2027 revenue of $5.75B-$5.85B and non-GAAP EPS of $12-$12.25 while accelerating $1.85B+ shareholder returns (NYSE:RMD)
· seekingalpha.com
ResMed (RMD) Q4 FY2026 earnings call recap with FY2027 revenue/EPS guidance, margin outlook, Astral headwinds and portfolio moves—read key takeaways.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...